In our analysis, the most common molecular aberration was observed in the expression of the tumor suppressor gene PTEN. We observed complete loss or very faint PTEN expression in 10 of 19 (53%) of tested tumor samples, highlighting the therapeutic target potential of the PI3K/AKT/mTOR pathway. The gene discussed is AKT1; the disease is neoplasm.